Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy

Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/qpvLFsAe0x

Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient mortality rate (9.17% vs. 4.68%; p=0.001)( (aOR=2.02) #ACR20 Abstr#1390 https://t.co/qWUMkJR40d

• https://meet.acrconvergence.org/meetings/virtual/SgtHW8Sz524uXMjWu

Nintedanib in rheum ILD (RA/SSc/CTD) I appreciate the volumes might not seem like much, but: - in first 1y Rx 20% more are spared a FVC decline>10% - biggest diff in UIP-like pattern With the right patient selection, nintedanib does have its place! #ACR20 ABST1048/1049 @RheumNow https://t.co/jGZdR84bBU

Racial disparity in SSc-ILD pts treated with MMF? 1️⃣Early initiation of MMF significantly slowed ⬇️ of FVC% 2️⃣No difference in MMF efficacy between African-Americans and non-AA 3️⃣AA had baseline lower FVC% @RheumNow #ACR20 Abs0929 https://t.co/rtsbe7OCvA

Interesting data re HCQ decreasing new PAH in Early SSc #scleroderma Not sure I believe it. Confounding, diff subsets get #hydroxycholoroquine due to inflammatory arthritis etc. Maybe a big pragmatic RCT is warranted as PAH is lethal @RheumNow @CRASCRRheum #ACR20 abstr#925 https://t.co/Al81sMGgxI

• https://twitter.com/doctorrbc/status/1325079846679089152

Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension when initiated early (<18 months). Prospective, observational study. @RheumNow #ACR2020 Abs#0925 https://t.co/nj0mNAY5Pe